Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription


2 Aging (Albany NY)
1 Ann Med
1 Ann Transl Med
1 Asia Ocean J Nucl Med Biol
1 BMC Cancer
1 Cancer Cell
1 Curr Oncol Rep
1 Ecotoxicol Environ Saf
1 Exp Ther Med
1 Front Bioeng Biotechnol
2 Front Oncol
1 Future Sci OA
1 Hinyokika Kiyo
1 Int J Cancer
1 Int J Mol Sci
1 Int Urol Nephrol
1 J Cancer Res Ther
1 J Endourol
6 J Urol
2 Lancet Oncol
1 Medicine (Baltimore)
1 Oncologist
1 Open Med (Wars)
2 Pathol Oncol Res
1 Scand J Urol
1 Sci Transl Med
1 Tuberk Toraks
1 Urol J
2 Urol Oncol
2 Urologiia
1 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Aging (Albany NY)

  1. CHEN MK, Zhou JH, Wang P, Ye YL, et al
    BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell.
    Aging (Albany NY). 2021;13.
    PubMed         Abstract available

  2. XU X, Xie B, Li S, Wang S, et al
    Association of dietary tomato intake with bladder cancer risk in a prospective cohort of 101,683 individuals with 12.5 years of follow-up.
    Aging (Albany NY). 2021;13.
    PubMed         Abstract available

    Ann Med

  3. HAO H, Chen H, Xie L, Liu H, et al
    YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition.
    Ann Med. 2021;53:1169-1177.
    PubMed         Abstract available

    Ann Transl Med

  4. CHEN H, Liu Y, Cao C, Xi H, et al
    CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers.
    Ann Transl Med. 2021;9:761.
    PubMed         Abstract available

    Asia Ocean J Nucl Med Biol

  5. GHORBANI H, Zarifmahmoudi L, Sadeghi R, Soltani S, et al
    Bowel visualization on the lymphoscintigraphy images of a bladder cancer patient due to inadvertent injection of the tracer in the rectal wall.
    Asia Ocean J Nucl Med Biol. 2021;9:177-179.
    PubMed         Abstract available

    BMC Cancer

  6. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    PubMed         Abstract available

    Cancer Cell

  7. MEZA L, Salgia NJ, Patel KC, Pal SK, et al
    Learning from BISCAY: The future of biomarker-based trial design in bladder cancer.
    Cancer Cell. 2021;39:910-912.
    PubMed         Abstract available

    Curr Oncol Rep

  8. SLOVACEK H, Zhuo J, Taylor JM
    Approaches to Non-Muscle-Invasive Bladder Cancer.
    Curr Oncol Rep. 2021;23:105.
    PubMed         Abstract available

    Ecotoxicol Environ Saf

  9. LOU Y, Ma C, Liu Z, Shi J, et al
    Antimony exposure promotes bladder tumor cell growth by inhibiting PINK1-Parkin-mediated mitophagy.
    Ecotoxicol Environ Saf. 2021;221:112420.
    PubMed         Abstract available

    Exp Ther Med

  10. SPASOVA V, Mladenov B, Rangelov S, Hammoudeh Z, et al
    Clinical impact of copy number variation changes in bladder cancer samples.
    Exp Ther Med. 2021;22:901.
    PubMed         Abstract available

    Front Bioeng Biotechnol

  11. JANEV A, Ramuta TZ, Tratnjek L, Sardoc Z, et al
    Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models.
    Front Bioeng Biotechnol. 2021;9:690358.
    PubMed         Abstract available

    Front Oncol

  12. WANG R, Zheng Z, Mao S, Zhang W, et al
    Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:632459.
    PubMed         Abstract available

  13. DONG Y, Ma WM, Shi ZD, Zhang ZG, et al
    Role of NRP1 in Bladder Cancer Pathogenesis and Progression.
    Front Oncol. 2021;11:685980.
    PubMed         Abstract available

    Future Sci OA

  14. FERRO M, Baba DF, de Cobelli O, Musi G, et al
    Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.
    Future Sci OA. 2021;7:FSO709.
    PubMed         Abstract available

    Hinyokika Kiyo

  15. HIRANO S, Matsumoto K, Shiono Y, Nakamura M, et al
    [Clinicopathological Characteristics of Adolescent and Young-Adult Patients with Bladder Cancer].
    Hinyokika Kiyo. 2021;67:221-224.
    PubMed         Abstract available

    Int J Cancer

  16. VAN DOEVEREN T, Nakauma-Gonzalez JA, Mason AS, van Leenders GJLH, et al
    The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.
    Int J Cancer. 2021;148:981-987.
    PubMed         Abstract available

    Int J Mol Sci

  17. ERMAN A, Kamensek U, Dragin Jerman U, Pavlin M, et al
    How Cancer Cells Invade Bladder Epithelium and Form Tumors: The Mouse Bladder Tumor Model as a Model of Tumor Recurrence in Patients.
    Int J Mol Sci. 2021;22.
    PubMed         Abstract available

    Int Urol Nephrol

  18. KOIE T, Hashimoto Y, Imai A, Yoneyama T, et al
    Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution.
    Int Urol Nephrol. 2021;53:275-280.
    PubMed         Abstract available

    J BUON

  19. TZELVES L, Xenou D, Skolarikos A, Varkarakis I, et al
    Association of obesity and other anthropometric characteristics with bladder cancer risk: a systematic review and meta-analysis of longitudinal cohort studies.
    J BUON. 2021;26:1040-1055.
    PubMed         Abstract available

  20. GOKYER A, Kucukarda A, Kostek O, Sayin S, et al
    The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.
    J BUON. 2021;26:1034-1039.
    PubMed         Abstract available

    J Cancer Res Ther

  21. WANG Z, Han C, Xu Y, Yu X, et al
    The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin vaccine therapy in patients with nonmuscle invasive bladder cancer.
    J Cancer Res Ther. 2021;17:625-629.
    PubMed         Abstract available

    J Endourol

  22. BABOUDJIAN M, Tadrist A, Lechevallier E
    Response to Editorial Comment: "Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?" by Tadrist e
    J Endourol. 2021;35:1049-1050.

    J Urol

  23. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    PubMed         Abstract available

  24. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed         Abstract available

  25. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    PubMed         Abstract available

  26. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    PubMed         Abstract available

  27. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.

  28. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    PubMed         Abstract available

    Lancet Oncol

  29. POWLES T, Csoszi T, Ozguroglu M, Matsubara N, et al
    Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2021;22:931-945.
    PubMed         Abstract available

  30. ZENGIN ZB, Meza L, Pal SK, Grivas P, et al
    Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
    Lancet Oncol. 2021;22:894-896.

    Medicine (Baltimore)

  31. SHEN C, Zhou K, Wang W, Zhang Y, et al
    The prognostic value of preoperative serum albumin in patients with bladder urothelial carcinoma undergoing transurethral resection of bladder tumor: A prospective cohort study.
    Medicine (Baltimore). 2021;100:e26548.
    PubMed         Abstract available


  32. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed         Abstract available

    Open Med (Wars)

  33. ZHU J, Zhang F
    Circular RNA VANGL1 knockdown suppressed viability, promoted apoptosis, and increased doxorubicin sensitivity through targeting miR-145-5p to regulate SOX4 in bladder cancer cells.
    Open Med (Wars). 2021;16:1010-1021.
    PubMed         Abstract available

    Pathol Oncol Res

  34. CHEN M, Nie Z, Cao H, Gao Y, et al
    Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
    Pathol Oncol Res. 2021;27:598460.
    PubMed         Abstract available

  35. JEONG H, Oh HE, Kim H, Lee JH, et al
    Upregulation of Fatty Acid Transporters is Associated With Tumor Progression in Non-Muscle-Invasive Bladder Cancer.
    Pathol Oncol Res. 2021;27:594705.
    PubMed         Abstract available

    Scand J Urol

    The devil is in the selected details: second-look resection in T1 bladder cancer.
    Scand J Urol. 2021 Jul 13:1. doi: 10.1080/21681805.2021.1948099.

    Sci Transl Med

  37. CHRYSOSTOMOU S, Roy R, Prischi F, Thamlikitkul L, et al
    Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed         Abstract available

    Tuberk Toraks

  38. OZGUL HA, Altay C, Basara Akin I, Bozkurt O, et al
    [Evaluation of solid pulmonary nodules in patients with bladder cancer with computed tomography based texture analysis method: Is it possible to differentiate metastatic - non-metastatic nodules?]
    Tuberk Toraks. 2021;69:227-236.
    PubMed         Abstract available

    Urol J

  39. LUO C, Lei T, Zhao M, Meng Q, et al
    The Role of NPM1 in the Invasion and Migration of Drug Resistant Bladder Cancer.
    Urol J. 2021 Jul 6. pii: 6087. doi: 10.22037/uj.v18i.6087.
    PubMed         Abstract available

    Urol Oncol

  40. SCHULZ GB, Todorova R, Braunschweig T, Rodler S, et al
    PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
    Urol Oncol. 2021 Jul 11. pii: S1078-1439(21)00260.
    PubMed         Abstract available

  41. LAUKHTINA E, Mori K, D Andrea D, Moschini M, et al
    Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2021 Jul 12. pii: S1078-1439(21)00267.
    PubMed         Abstract available


  42. KOMYAKOV BK, Sergeev AV, Fadeev VA, Al-Attar TH, et al
    [Long-term results of radical surgery treatment of patients with bladder cancer].
    Urologiia. 2021;:104-109.
    PubMed         Abstract available

  43. ZUBKOV AY, Nuriev IR, Sitdykova ME
    [Improvement of oncologic results of transurethral resection in the treatment of non-muscle-invasive bladder cancer].
    Urologiia. 2021;:110-113.
    PubMed         Abstract available

    World J Urol

  44. WEYERER V, Stoehr R, Bertz S, Lange F, et al
    Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    World J Urol. 2021 Jul 14. pii: 10.1007/s00345-021-03788.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.